Skip to content
Agentic OS
Menu

Intelligence / B2B SaaS / Acquisitions / International Stem Cell CORP

M&Asold assets or a business (SEC 8-K)8 Sept 2026

International Stem Cell CORP

8 Sept 2026: Sold assets or a business (SEC 8-K) · Pharma and biotech. Recorded in the SEC EDGAR full-text search.

View the source record

Filed
8 Sept 2026
Ticker
ISCO
Role
Sold assets or a business
Sector
Pharma and biotech
Sic
2834
Items
2.01, 9.01
Summary
As previously disclosed, on July 10, 2026, International Stem Cell Corporation, a Delaware corporation (the "Company" or "Parent"), International Stem Cell Corporation, a California corporation ("Intermediate" and, together with Parent, "Seller"), Lifeline Cell Technology, LLC, a California limited liability company ("
Location
San Diego, CA
State
California
Country
United States
SEC CIK
1355790
Reference
0001683168-26-007007
What this signal means

Integration means consolidating tools and vendors: the buyer re-platforms the target, and an acquired company's stack is reviewed by its new owner.

  1. Completed an acquisition leads with 189 of 292, then Sold assets or a business (82).
  2. 103 added in the 30 days to 19 Nov 2026.
Reach them with AOS

Find the decision makers at International Stem Cell CORP

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this m&a signal, for your approval.

Start free

More in Sold assets or a business

Acquisitions

See all

Source: SEC EDGAR full-text search, data to 19 Nov 2026. Every Form 8-K reporting Item 2.01 (completion of an acquisition or disposition of assets) filed with the SEC in the last 90 days. The role (buyer, company acquired, seller) is read from the filing's own wording, which is quoted on each row. AOS shows what the public record says; it does not verify or endorse the company.